Tarlatamab in small cell lung cancer (SCLC): Safety and efficacy analyzed by baseline brain metastasis
Authors
Champiat, S.Boyer, M. J.
Govindan, R.
Paz-Ares, L. G.
Owonikoko, T. K.
Borghaei, H.
Izumi, H.
Steeghs, N.
Blackhall, Fiona H
Terbuch, A.
Johnson, M. L.
Yoshida, T.
He, K.
Zhang, Y. Y.
Jones, S.
Chen, X.
Martinez, P.
Hummel, H. D.
Affiliation
Gustave Roussy, Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Villejuif, FranceIssue Date
2023
Metadata
Show full item recordCitation
Champiat S, Boyer MJ, Govindan R, Paz-Ares LG, Owonikoko TK, Borghaei H, et al. Tarlatamab in small cell lung cancer (SCLC): Safety and efficacy analyzed by baseline brain metastasis. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772003656.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2023.41.16_suppl.8582Additional Links
https://dx.doi.org/10.1200/JCO.2023.41.16_suppl.8582Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2023.41.16_suppl.8582